RAD202

Radiopharmaceutical

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
HER2-Positive Advanced Solid Tumors

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, 10 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
RAD202: this drugPhase 1RadiopharmaceuticalHER2not yet gradedNo reviewed efficacy summary
Margetuximab (Margenza)
Approved(overall)
Monoclonal antibodyHER2not yet gradedNo reviewed efficacy summary
Trastuzumab Deruxtecan
Approved(overall)
Antibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8)
Tucatinib
Approved(overall)
Small moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Zanidatamab
Approved(overall)
Multispecific antibodyHER2Weak signal
NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023)
Disitamab Vedotin
Phase 3(overall)
Antibody–drug conjugateHER2Partial signal
NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91).
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
Trastuzumab Brengitecan
Phase 3(overall)
Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary
Trastuzumab Pamirtecan
Phase 3(overall)
Antibody–drug conjugateHER2Partial signal
NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis.
Trastuzumab Rezetecan
Phase 3(overall)
Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary
Bizrolertinib
Phase 2/3(overall)
Small moleculeHER2not yet gradedNo reviewed efficacy summary
HRS-4508
Phase 2(overall)
Small moleculeHER2not yet gradedNo reviewed efficacy summary
177Lu-DWJ155
Phase 1(overall)
RadiopharmaceuticalHER2not yet gradedNo reviewed efficacy summary
BL-M17D1
Phase 1(overall)
Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary
KJ015
Phase 1(overall)
Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary
MT-304
Phase 1(overall)
RNA / oligonucleotideHER2not yet gradedNo reviewed efficacy summary
NVL-330
Phase 1(overall)
Small moleculeHER2not yet gradedNo reviewed efficacy summary
GSK6855547
—(overall)
Small moleculeHER2not yet gradedNo reviewed efficacy summary

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow RAD202 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 1HER2-Positive Advanced Solid TumorsRecruiting
Est. primary completion 2027-12 · NCT06824155 · CT.gov ↗
What to watch

See the full readout calendar ↗